18 results about "Blood markers" patented technology

The application discloses a CKD and IgAN early detection method based on blood mass spectrum analysis, utilizes liquid chromatography-tandem mass spectrometry technology to detect 24 kinds of compounds of a plasma sample in a targeted manner, utilizes a logic regression to establish an early detection model of CKD and IgAN, and verifies the prediction accuracy of CKD and IgAN in a cohort. Through analysis of plasma samples of healthy controls and CKD patients (including IgAN and non-IgAN patients), it is proved that the melatonin or melatonin+tryptophan level in the plasma is an effective method for detecting early CKD, and the melatonin, tryptophan, indole-3-lactic acid, indole-3-carboxylic acid, kynurenic acid and indole-3-methyl aldehyde are effective methods for detecting early IgAN. The application provides effective blood markers for early detection of CKD and IgAN.

The application discloses a kind of microcolumn-photon crystal composite device and preparation method thereof for multiple blood markers detection, wherein the composite device includes flexible substrate to distribute each microcolumn on the flexible substrate;Flexible substrate is curled to form a three-dimensional capillary channel, and each microcolumn is distributed on the inner wall of three-dimensional capillary channel;The surface of each microcolumn is covered with photon crystal for enhancing the sensitivity of low-concentration biomarker detection.The composite device and preparation method thereof form a three-dimensional capillary channel by curling flexible substrate, promote rapid and stable liquid transmission, effectively overcome the limitations of traditional plane substrate;By covering the surface of each microcolumn with photon crystal, the sensitivity of low-concentration biomarker detection can be enhanced when detecting.

The invention relates to a chemiluminiscence detection kit for a blood marker pTau217 of an Alzheimer's disease and application of the chemiluminiscence detection kit. The kit comprises a magnetic microsphere suspension coated with a pTau217 capture antibody; a pTau217 detection antibody labeled by PEG12 (Polyethylene Glycol) < 12 > biotin; streptavidin marked by acridinium ester; an interference eliminating liquid; a washing liquid; pre-excitation liquid and excitation liquid. A PEG12-biotin-streptavidin system is introduced, a large amount of acridinium ester is coupled through streptavidin, a total luminescence signal is amplified, and the detection sensitivity and precision of the chemiluminescence pTau217 are greatly improved. Meanwhile, interference elimination liquid containing dioxane and Proclin300 is adopted and mixed with a plasma sample, then antibody capturing microspheres are added, non-specific adsorption of lipid and binding protein thereof in plasma on the surfaces of the microspheres is weakened, and the detection accuracy is greatly improved.

This invention discloses an antibody for detecting apolipoprotein E4 and its application, specifically involving a detection antibody and kit for detecting ApoE4, a blood marker of Alzheimer's disease. Based on this antibody and kit, the presence of apolipoprotein E4 can be accurately detected.

The invention relates to an Alzheimer's disease blood marker flow type fluorescence luminescence multi-joint detection kit and application thereof. The Alzheimer's disease blood marker flow type fluorescence luminescence multi-joint detection kit comprises a capture microsphere mixed solution, a detection antibody mixed solution, a streptavidin-phycoerythrin conjugate, an interference elimination solution and a washing solution. The bihexanamide-biotin is labeled on the detection antibody, the steric hindrance of combination of the streptavidin-phycoerythrin conjugate and the biotin on the detection antibody is reduced through bihexanamide, more phycoerythrin can be combined on a single antibody, a fluorescence signal is remarkably enhanced, and the detection sensitivity is greatly improved. An interference elimination solution containing dimethyl sulfoxide and Proclin300 at the same time is adopted and mixed with a plasma sample, then a capture antibody and a detection antibody are added, non-specific adsorption of lipids and binding proteins thereof in plasma on the surfaces of microspheres is weakened, and the detection accuracy is greatly improved. According to the method, a machine learning model based on a logistic regression algorithm is constructed through a joint detection result of seven markers in three layers, and the judgment accuracy is cooperatively improved.

The invention provides a Chinese ladiestresses root extract as well as a preparation method, a related product and application thereof, and belongs to the technical field of traditional Chinese medicine extraction. The preparation method comprises the following steps: mixing pedicularis chinensis and ketone, and performing reflux leaching and separation to obtain a leaching solution and medicine residues; recovering the solvent from the leaching solution to obtain a Chinese ladiestresses root extract; mixing the medicine residue with water, decocting, centrifuging the decoction, reserving the supernatant, and carrying out alcohol precipitation to obtain crude polysaccharide; reacting the crude polysaccharide with sodium periodate to obtain oxidized paniculate helminthostachys rhizome polysaccharide; and mixing 5-15 parts by weight of the paniculate helichrysum herb extract, 10-30 parts by weight of the oxidized paniculate helichrysum herb polysaccharide and 100 parts by weight of water, and carrying out ultrasonic dispersion and drying to obtain the paniculate helichrysum herb extract. The spiranthes sinensis extract obtained by the method can form a submicron-level particle structure, and can better reduce the foot swelling score of rheumatoid arthritis mice, improve the blood marker index of model mice and reduce the occurrence of hemolysis side effects.

The invention discloses an antibody for detecting beta-amyloid protein and application thereof, and particularly relates to a detection antibody and a kit for detecting Alzheimer's disease blood markers A beta 1-40 and A beta 1-42, the kit comprises three antibodies aiming at different antigenic determinants of beta-amyloid protein, based on the antibody and the kit, the existence of beta-amyloid protein can be accurately detected.

The application discloses a kind of S wave band high-power microwave biological effect test and evaluation method, comprising: selecting microwave test site satisfying far-field condition and constructing S frequency band high-power microwave biological effect device;According to test scheme, adjust output power, repetition frequency, pulse width and irradiation time to form different irradiation conditions, and apply S wave band high-power microwave irradiation to the biological body to be measured;At the preset time point after irradiation ends, the behavior of the biological body to be measured is tested and blood routine and biochemical index detection is carried out;Based on the obtained behavior characteristic data, blood routine and biochemical index data, a multi-parameter collaborative evaluation model of the three-level mapping relationship between physical stimulation intensity, behavior abnormality and blood markers is established to evaluate the influence of S wave band high-power microwave on the biological body.The application can study the influence of S wave band high-power microwave on the behavior state and blood routine parameters of the biological body under the conditions of output power, repetition frequency, pulse width, irradiation time and other variables.

The application provides a gold-silver alloy nanoflower SERS substrate and a preparation method and application thereof. 3+ and Ag + The preparation method is as follows: an aluminum foil paper substrate is placed in a growth solution containing Au 3+ and Ag + , a gold-silver alloy nanoflower array pattern layer with a multi-level branch structure is formed on the surface of the aluminum foil paper substrate by a displacement reaction of aluminum and noble metal ions in situ. The gold-silver alloy nanoflower array pattern layer has rich nanotips and a three-dimensional rough structure, can form a large number of electromagnetic 'hot spots', and can significantly enhance the Raman signal intensity. Relying on the excellent SERS enhancement performance, the gold-silver alloy nanoflower SERS substrate is applied to an immune recognition mediated sandwich detection mode, and high-sensitivity and accurate detection of a hidden blood marker in a fecal sample is realized. The preparation process is simple, the cost is low, and complex equipment is not needed; the obtained SERS substrate has strong stability and excellent repeatability, and can meet the needs of early screening and on-site rapid detection of digestive diseases.

The invention relates to the technical field of biomedical detection, and discloses a plasma biomarker protein determination method for breast cancer detection, the non-invasive detection of breast cancer is realized by detecting the WFIKKN2 protein level in plasma through ELISA, and the method comprises the steps of collection and treatment of a plasma sample, ELISA detection and diagnosis result determination based on a specific threshold. The problems that in an existing breast cancer monitoring method, biopsy applicability is poor, CT / MRI has radiation and cost are solved, the defect that an existing blood marker is insufficient in sensitivity is overcome, and the method has the advantages of being high in sensitivity, easy and convenient to operate, low in cost, high in safety and the like and can be effectively used for breast cancer detection, illness condition grading and postoperative monitoring.

The invention discloses a muscle quality assessment aided decision-making method based on double-source features, which comprises the following steps: firstly, collecting multi-modal data of a patient, extracting modal features, then adopting time sequence enhancement, obtaining DXA whole body, DXA leg and blood test features, and then carrying out modal correlation calculation, namely, calculating the correlation among the modal features of the DXA whole body, the DXA leg and blood test three modes; then, a relation graph between modes is constructed through graph convolution, mode relation fusion is carried out, finally, muscle quality prediction is carried out, and muscle quality evaluation is completed. According to the method, the DXA whole body and leg images and the double-source features of blood indexes are utilized, multi-modal relation modeling and time sequence enhancement are combined, high-precision explainable prediction of muscle quality is achieved, the whole body and leg muscle features can be distinguished, blood test changes can be dynamically reflected, and auxiliary decision support is provided for sarcopenia screening.

The application belongs to the field of molecular diagnosis, and discloses application of a blood marker in preparation of a diagnostic reagent for idiopathic benign paroxysmal positional vertigo. It is found for the first time that LRG1 in blood is obviously increased in the acute attack period of idiopathic benign paroxysmal positional vertigo, which indicates that the increase of blood LRG1 is a blood marker for dizziness of idiopathic benign paroxysmal positional vertigo, and can be used as auxiliary diagnosis in clinic.

The present disclosure relates to a method for determining a blood marker, a blood marker and a kit. The method comprises obtaining a set of fragments for a first region in a cancer blood sample, the first region comprising a plurality of methylation sites. The method also includes determining a first distribution of one or more methylated haplotypes associated with the set of fragments. The method further includes determining the first region as a blood marker associated with the cancer in response to determining that the first profile and a second profile corresponding to the healthy blood sample satisfy a predetermined condition. In this way, the sensitivity and specificity of detection can be significantly improved by using a methylation pattern of a plurality of adjacent sites at the same time compared to only seeing a single site.

This invention provides a gold-silver alloy nanoflower SERS substrate, its preparation method, and its application. The preparation method involves placing an aluminum foil paper substrate in an Au-containing... 3+ and Ag + In a growth solution, a gold-silver alloy nanoflower array pattern layer with a multi-level branched structure is grown in situ on the surface of an aluminum foil substrate using a displacement reaction between aluminum and noble metal ions. This gold-silver alloy nanoflower array pattern layer has abundant nano-tip and three-dimensional rough structure, which can form a large number of electromagnetic "hot spots" and significantly enhance the Raman signal intensity. Based on its excellent SERS enhancement performance, this gold-silver alloy nanoflower SERS substrate is applied to the immune recognition-mediated sandwich detection mode to achieve highly sensitive and accurate detection of occult blood markers in fecal samples. The preparation process of this invention is simple, low-cost, and requires no complex equipment. The resulting SERS substrate has strong stability and excellent repeatability, which can meet the needs of early screening and rapid on-site detection of digestive tract diseases.

The application discloses an immunosensor for detecting neurofilament light chain protein of Alzheimer's disease based on a two-dimensional metal organic framework and a preparation method thereof, and belongs to the technical field of biological detection sensors. The electrode modified with RuMOFNSs-Ab2 conjugates and Au@MoS2-Ab1 conjugates is used as a working electrode, and the electrode is a sandwich type electrochemiluminescence immunosensor based on two-dimensional RuMOFNSs / Au@MoS2, can be used for detecting the blood marker NfL of Alzheimer's disease, provides a thought for the analysis and detection field of NfL, and provides a reference for clinical medical detection.

The use of an LRG1 quantitative reagent in the preparation of a diagnostic or auxiliary diagnostic reagent for nerve entrapment injuries of the limbs, and a diagnostic or auxiliary diagnostic system for nerve entrapment injuries of the limbs comprising an LRG1 quantitative device. With nerve entrapment caused by limb tumors, the average level of LRG1 in blood is elevated compared with that of normal people, and the elevation becomes more significant with aggravation of the injury, indicating that LRG1, as a peripheral blood marker for nerve entrapment caused by limb tumors, has a relatively high sensitivity and specificity.

This invention discloses a Mycoplasma pneumoniae antibody detection kit based on immunoturbidimetry, belonging to the field of clinical immunology testing. It includes solutions R1 and R2. Solution R1 is a dispersion of double-coupled latex microspheres coated with natural Mycoplasma pneumoniae antigens, and solution R2 is a sample diluent containing an enhancer. The test samples can be serum, plasma, or whole blood samples, and it is applicable to biochemical analyzers, protein analyzers, or combined blood cell and immunoturbidimetric analyzers. The kit prepared by this invention can be used on various instruments, has a wide range of detection targets, and can be coupled with other instruments to detect various clinically valuable blood indicators, further shortening the testing time. It solves the problems of poor accuracy, low efficiency, and limited application scenarios caused by the subjective interpretation of results, long processing time, and limited applicability of blood samples in existing technologies. It can effectively simplify the testing process and improve diagnostic efficiency.

Presented herein are methods of identifying a subject who has, or is at risk of developing Alzheimer's disease comprising determining a presence or amount of 2-aminoethyl dihydrogen phosphate or taurine in the blood, or a blood product, obtained from the subject. Also presented herein are methods of preventing, treating or delaying the onset of Alzheimer's disease.